Disease Characteristics and Treatment Outcomes of Myeloma Patients Under 50 Years of Age: An Analysis of the Balkan Myeloma Study Group

• DOI: 10.1016/j.clml.2024.12.017
• Publication Date: 2025-01-08T00:22:06Z
• Authors: Despina Fotiou; Sorina Nicoleta B...; Eirini Katodritou; Meral Beksac; Jelena Bila; Emmanouil Spanoud...; Josip Batinić; Daniel Coriu; Sinziana Barbu; Catalin Danaila; Dimitra Dalampira; Angeliki Sevastoudi; Guldane Cengiz Seval; Selami Koçak Toprak; Aleksandra Sreten...; Olivera Markovic; Toni Valkovic; Zorica Cvetkovic; Fenia Theodorakakou; Maria Gavriatopoulou; Evangelos Terpos; Meletios A. Dimop...; Efstathios Kastritis

Multiple myeloma (MM) is predominantly a disease of the elderly, but approximately 10% patients are younger than 50 years at diagnosis. METHODS: This study aimed to investigate clinical characteristics, treatment outcomes, and prognostic factors in MM using retrospective data from Balkan Myeloma Study Group registry. RESULTS: A total 350 under old were included, comprising 10.4% overall cohort. The found that had lower rates renal impairment anemia higher incidence lytic bone adverse cytogenetics. Treatment regimens, including proteasome inhibitors immunomodulatory agents, comparable between older patients, significantly better complete response survival (OS). 5- 10-year OS 76% 64%, respectively, with projected median exceeding 15 years. Factors such as anemia, hypercalcemia, high-risk cytogenetics associated worse outcomes. Autologous stem cell transplantation (ASCT) emerged key contributor improved progression-free (PFS) OS. In conclusion, exhibit distinct features benefit intensified approaches, underscoring need for tailored therapies achieve potential cure.